1. Home
  2. AADI vs BGSF Comparison

AADI vs BGSF Comparison

Compare AADI & BGSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AADI
  • BGSF
  • Stock Information
  • Founded
  • AADI 2011
  • BGSF 2007
  • Country
  • AADI United States
  • BGSF United States
  • Employees
  • AADI N/A
  • BGSF N/A
  • Industry
  • AADI Biotechnology: Pharmaceutical Preparations
  • BGSF Professional Services
  • Sector
  • AADI Health Care
  • BGSF Consumer Discretionary
  • Exchange
  • AADI Nasdaq
  • BGSF Nasdaq
  • Market Cap
  • AADI 77.5M
  • BGSF 66.0M
  • IPO Year
  • AADI N/A
  • BGSF N/A
  • Fundamental
  • Price
  • AADI $2.79
  • BGSF $4.97
  • Analyst Decision
  • AADI Hold
  • BGSF
  • Analyst Count
  • AADI 3
  • BGSF 0
  • Target Price
  • AADI $1.75
  • BGSF N/A
  • AVG Volume (30 Days)
  • AADI 114.1K
  • BGSF 11.0K
  • Earning Date
  • AADI 03-12-2025
  • BGSF 03-12-2025
  • Dividend Yield
  • AADI N/A
  • BGSF N/A
  • EPS Growth
  • AADI N/A
  • BGSF N/A
  • EPS
  • AADI N/A
  • BGSF N/A
  • Revenue
  • AADI $25,070,000.00
  • BGSF $281,656,000.00
  • Revenue This Year
  • AADI $8.43
  • BGSF N/A
  • Revenue Next Year
  • AADI $5.41
  • BGSF $5.63
  • P/E Ratio
  • AADI N/A
  • BGSF N/A
  • Revenue Growth
  • AADI 7.80
  • BGSF N/A
  • 52 Week Low
  • AADI $1.21
  • BGSF $4.70
  • 52 Week High
  • AADI $3.81
  • BGSF $10.50
  • Technical
  • Relative Strength Index (RSI)
  • AADI 48.57
  • BGSF 39.14
  • Support Level
  • AADI $2.56
  • BGSF $4.90
  • Resistance Level
  • AADI $2.94
  • BGSF $5.19
  • Average True Range (ATR)
  • AADI 0.13
  • BGSF 0.19
  • MACD
  • AADI 0.01
  • BGSF 0.01
  • Stochastic Oscillator
  • AADI 57.50
  • BGSF 40.30

About AADI Aadi Bioscience Inc.

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

About BGSF BGSF Inc.

BGSF Inc is a provider of workforce solutions operating primarily in the U.S. across two segments: Property Management and Professional. In the Property Management segment, BGSF offers office and maintenance talent to clients, facilitating their staffing needs with short-term and consulting solutions. The Professional segment specializes in IT, offering skilled professionals in SAP, Workday, and other areas to Fortune 500 companies and consulting firms nationwide. BGSF's workforce services include on-demand assignments, consulting, and managed solutions, allowing clients to flexibly manage their workforce needs. With a focus on converting fixed personnel costs to variable expenses, BGSF enables companies to effectively address fluctuations in demand while optimizing costs.

Share on Social Networks: